Take Part in the Latest LLS Web Program for Chronic Lymphocytic Leukemia

The Leukemia & Lymphoma Society is offering another FREE telephone/web education program, this one designed for patients, caregivers and healthcare professionals.

The latest program is Chronic Lymphocytic Leukemia (CLL): Current and Emerging Therapies.

Date

Wednesday June 18, 2014

Time

1:00 PM to 2:30 PM Eastern
10:00 AM to 11:30 AM Pacific

Featured Speaker

Thomas J. Kipps, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Deputy Director for Research
UC San Diego Moores Cancer Center
La Jolla, CA

Participating in an LLS program like this can help you learn more about:

  • The goal of CLL treatment
  • How staging influences treatment planning
  • Current treatment options for CLL (and there are many)
  • Emerging therapies and options
  • Managing side effects
  • The importance of open communication with your treatment team
  • And much more

Register for this FREE program by clicking here.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap